Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Back

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

London Nottingham London London Edinburgh Cardiff Northampton Warwick Bristol

Medical Conditions

Breast Neoplasms
Triple Negative Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2022 Dec 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Experimental drug. Provided in 100mg vials. IV infusion.

Intervention Arm Group : Dato-DXd;

Intervention Type : DRUG
Intervention Description : IV Infusion. Active comparator

Intervention Arm Group : Investigator's Choice of Chemotherapy (ICC);

Intervention Type : DRUG
Intervention Description : IV infusion. Active comparator

Intervention Arm Group : Investigator's Choice of Chemotherapy (ICC);

Intervention Type : DRUG
Intervention Description : IV infusion. Active comparator

Intervention Arm Group : Investigator's Choice of Chemotherapy (ICC);

Intervention Type : DRUG
Intervention Description : Tablet. Oral route of administration. Active comparator

Intervention Arm Group : Investigator's Choice of Chemotherapy (ICC);

Intervention Type : DRUG
Intervention Description : IV infusion. Active comparator

Intervention Arm Group : Investigator's Choice of Chemotherapy (ICC);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    London
    SW17 0QT
  • Research Site
    Nottingham
    NG5 1PB
  • Research Site
    London
    EC1A 7BE
  • Research Site
    London
    SE1 9RT
  • Research Site
    Edinburgh
    EH4 2XU
  • Research Site
    Cardiff
    CF14 2TL
  • Research Site
    Northampton
    NN1 5BD
  • Research Site
    Warwick
    CV34 5BW
  • Research Site
    Bristol
    BS2 8ED


The study is sponsored by AstraZeneca and is in collaboration with Daiichi Sankyo.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05374512
Last updated 11 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top